United States · Industrial & Consumer Products · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Salarius Pharmaceuticals, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -164.02% | -0.29% | -0.29% | -0.29% | -0.3% | -0.3% |
|---|---|---|---|---|---|---|
| ROA | -116.05% | -0.15% | -0.15% | -0.15% | -0.15% | -0.15% |
| Total Assets | $3,022.97K | $3,022.97K | $3,022.97K | $3,022.97K | $3,022.97K | $3,022.97K |
| Net Income | -$5,575.78K | -$4.42K | -$4.42K | -$4.42K | -$4.42K | -$4.42K |